WE.SPEED.
We are delighted to announce the opening of ARENSIA Research Clinic in the USA, located in Phoenix, Arizona!
Our mission for the clinic in the US aligns seamlessly with ARENSIA's core values—providing early access to innovative therapies for patients and assisting Sponsors in achieving prompt first efficacy signals/Proof of Concept.
By establishing a dedicated clinic infrastructure exclusively focused on early patient trials, complete with our own staff, facilities, and equipment, we aim to significantly reduce the time required for patient recruitment compared to typical clinical trial sites, which often face challenges such as overcrowding, staff shortages, population competition, and lengthy contract negotiations.
Strategically positioned in one of the nation's fastest-growing and fifth-largest cities in the US (with 4.7 million inhabitants), Phoenix boasts a diverse population both ethnically and socio-economically. It serves as a notable retirement community with a specialized medical community catering to this demographic.
Located in the northern part of Phoenix, our clinic reaches patient pools across the entire metropolitan area, conveniently located within three minutes from an ER/ICU facility. It mirrors the setup of our clinics in Europe, featuring patient rooms, sample processing and storage rooms, a dedicated and access-controlled pharmacy, staff and monitor rooms, and more. The full-time team is already on board, undergoing intensive Phase I training at ARENSIA Clinics in Europe. Under the leadership of Prof. Dr. David Treiman, a neurologist, and the clinic's Medical Director, the team brings strong medical expertise and decades of clinical research experience. The team includes colleagues from ARENSIA Clinics in Europe, who are relocating to Phoenix to support medical and project operations.
The ARENSIA Clinic starts enrolling patients as of December. It will be exclusively dedicated to conducting Phase I and II protocol designs across NEUROLOGY, IMMUNO-INFLAMMATION, CARDIOVASCULAR, AND INFECTIOUS DISEASES. From mid-2024 onward, we will expand gradually into other therapeutic areas, adding ONCOLOGY, NEPHROLOGY, RESPIRATORY, etc.
In conjunction with ARENSIA facilities in Europe, we are committed to providing our sponsors with a unique and streamlined platform—featuring a select number of efficient ARENSIA Clinics, as opposed to the traditional large number of academic sites typically involved in executing Phase I and II patient trials. Our goal is to deliver unparalleled patient enrollment speed and a substantial overall budget reduction for early-phase patient trials.
Feel free to reach out to us for feasibility inquiries at ARENSIA Phoenix, as well as for in-person visits! In the meantime, we are available to address any questions you may have.
27.10.2023